Business
Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions
Exciting lineup of events showcasing real-world evidence of improved outcomes and what the future holds for Omnipod’s tubeless automated insulin delivery
About this update from Insulet Corporation
[{"type":"text","content":"\nExciting lineup of events showcasing real-world evidence of improved outcomes and what the future holds for Omnipod’s tubeless automated insulin delivery\n\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced an exciting lineup of events and product developments that will be discussed at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego, California, including new real-world evidence (RWE) of improved outcomes and optimization of care using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).\n\n\n“Insulet’s flagship product, Omnipod 5, is having an incredible impact on people with diabetes, including improved glycemic outcomes and better quality of life,” said Jim Hollingshead, Insulet President and CEO. “We are thrilled with the opportunity to present real-world evidence from the first year on Omnipod 5 in the U.S., and further educate diabetes clinicians on how they can improve care for their patients using our tubeless automated insulin delivery technology.”\n\n\nThe Company also announced two updates related to Omnipod 5. In order to provide smartphone control for customers who use iOS mobile technology, Insulet has submitted the Omnipod 5 App for iPhone to the FDA for 510(k) clearance. The user interface has been enhanced to align with the iOS operating system, and a new Custom Food feature has been added to the Omnipod 5 App for iPhone.\n\n\nAdditionally, progressing with the Company's goal to provide Omnipod 5 users with sensor of choice, Insulet will soon begin enrollment for the clinical study of Omnipod 5 with the integration of the Abbott FreeStyle Libre 2 sensor. The study will recruit up to 200 participants with type 1 diabetes in both the adult and pediatric age groups in the United Kingdom, France, and Belgium. The study is intended to demonstrate superior efficacy with Omnipod 5 compared to multiple daily injections, as measured by glycated hemoglobin.\n\n\nInsulet representatives will discuss these plans for Omnipod 5 future innovations at ADA.\n\n\nClinical Presentations\n\n\nThe Company will kick off ADA with a live presentation on Friday, June 23 at 3:15 p.m. PT with Dr. Rayhan Lal, Assistant Professor of Medicine and Pedia...